Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-1.85%-5.85%+12.28%+108.74% 45.66B
-1.31%-6.72%+13.91%+20.47% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.04%-6.66%+130.12%+640.04% 34.48B
-0.80%+0.61%+77.26%+56.26% 32.5B
-1.69%+17.20%-28.87%+476.77% 31.69B
Average -1.07%-0.66%+34.06%+176.03% 45B
Weighted average by Cap. -1.32%-1.28%+32.35%+150.62%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-